|[March 28, 2012]
VasoStitch access-and-closure system for nonsurgical deployment of transcatheter therapies has "unique benefits"
DANVILLE, Calif. --(Business Wire)--
a start-up medical technology company, announced today that its
technology was featured at the annual scientific meeting of the American
College of Cardiology (ACC) this week in Chicago. VasoStitch is
developing a percutaneous access-and-closure system for the nonsurgical
deployment of large-diameter transcatheter therapeutic devices, such as
Transcatheter Aortic Valve Implants (TAVI) and Endovascular Aneurysm
Repair (EVAR) devices. The VasoStitch system is designed to reduce
procedural complexity and eliminate the need for an "open" surgical
The challenge with percutaneous catheter-based cardiac procedures is
that a surgical cut-down is required for access and then closure.
VasoStitch has developed two platform technologies designed to access
and close percutaneous therapy sites without the need for open surgery,
thus making catheter-based interventions simpler and more accessible.
"At this time, surgical means of arterial or cardiac access and closure
for large-diameter, catheter-based interventions adds about 60 minutes
to a lengthy and complicated procedure. Consequently, a device that can
replicate the current 'gold standard' of surgical access and repair in a
more rapid and facile fashion will reduce healthcare costs dramatically,
enhance adoption of large-diameter cardiovascular and endovascular
therapies, and improve the efficiency of patient management," said David
W. J. Smith, President and CEO of VasoStitch. "We now look
forward to our First-in-Human milestone."
The "unique benefits" of the VasoStitch technology include: (1)
integrated access and closure; (2) optimal closure and healing; (3) ease
of use; (4) universal size; and, (5) cost-effectivenes.
VasoStitch was founded by Amir Belson, MD. Dr. Belson previously
founded NeoGuide Systems, a company that developed platform
technology for minimally invasive surgical procedures and was acquired
by Intuitive Surgical in 2009; more recently, Dr. Belson also has
founded Emboline, Modular Surgical, RadGuard Medical,
Thermocure, Vascular Pathways and ZipLine Medical.
is an emerging medical device company that is developing nonsurgical
transfemoral and transapical access-and-closure systems to
facilitate deployment of large-diameter transcatheter therapeutic
devices-designed to reduce procedural complexity and eliminate the need
for an "open" surgical procedure.
[ Back To TMCnet.com's Homepage ]